Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca/Pozen Target 2009 For Arthritis Combination Filing

This article was originally published in The Pink Sheet Daily

Executive Summary

Companies will initiate a Phase III clinical trial for PN400, a combination of naproxen and the esomeprazole.

You may also be interested in...



Pozen/AZ Combo Pill Could See Setback As FDA Reviews Trial Endpoints

Phase III studies of the NSAID/PPI combination are set to wrap up, but agency now is reviewing use of endoscopic gastric ulcers as an endpoint.

Pozen/AZ Combo Pill Could See Setback As FDA Reviews Trial Endpoints

Phase III studies of the NSAID/PPI combination are set to wrap up, but agency now is reviewing use of endoscopic gastric ulcers as an endpoint.

AstraZeneca, Pozen To Partner On Fixed-Dose Naproxen/Esomeprazole

AstraZeneca will oversee global manufacturing, marketing, sales and distribution for the arthritis pain compound.

Topics

UsernamePublicRestriction

Register

PS066696

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel